[Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].

医学 肺癌 表皮生长因子受体 内科学 不利影响 肿瘤科 进行性疾病 癌症 奥西默替尼 癌症研究 疾病 埃罗替尼
作者
Jingjing Wang,Yujia Chi,Hanxiao Chen,Bo Jia,Xiaoyu Zhai,Menglei Ma,Jianjie Li,Minglei Zhuo
出处
期刊:DOAJ: Directory of Open Access Journals - DOAJ 卷期号:25 (7): 493-500 被引量:1
标识
DOI:10.3779/j.issn.1009-3419.2022.102.26
摘要

Epidermal growth factor receptor (EGFR) and cellular-mesenchymal to epithelial transition factor (c-Met) are widely expressed on cancer cells. There is a synergistic effect of EGFR and HGF/c-Met pathways on proliferation, downstream activation of signal transduction and an additive effect. Studies show that combination of both signaling pathways could potentially be targeted in a synergistic fashion. Amivantamab, a bispecific monoclonal antibody targeting EGFR and c-Met, yielded robust and durable responses in a variety of clinicals trials. However, few researches have reported its efficacy in Chinese non-small cell lung cancer (NSCLC) patients. This study was conducted to evaluate the effectiveness and tolerance of Amivantamab in NSCLC patients with EGFR/MET gene abnormalities at Peking University Cancer Hospital.The study enrolled NSCLC patients who received Amivantamab in our hospital between August 2020 and December 2021, and analyzed the response, survival, and treatment-related adverse events.Fifteen patients were enrolled in this research, and six of them received Amivantamab treatment and the other nine patients received Amivantamab plus Lazertinib treatment. The rates of partial response (PR), stable disease (SD), and progressive disease (PD) were 46.7% (7/15), 46.7% (7/15) and 6.7% (1/15), respectively. The overall response rate (ORR) and disease control rate (DCR) were 28.6% (2/7) and 100.0% (7/7) in seven patients with EGFR exon 20 insertion, respectively. The ORR and DCR were 40.0% (2/5) and 100.0% (5/5) in five post-osimertinib EGFR-mutant patients, respectively. After a median follow-up of 8.7 months, the median progression-free survival and overall survival were not reached. The most common treatment-related adverse events were rash (86.7%), paronychia (80.0%), and infusion-related reactions (60.0%), and most of them were graded as 1 to 2. Grade 3 to 4 adverse events included rash (33.3%), alanine aminotransferase elevation (13.3%), gamma-glutamyl transpeptidase elevation (13.3%), peripheral edema (6.7%), thromboembolism (6.7%), interstitial lung disease (6.7%), and thrombocytopenia (6.7%).Amivantamab was effective in Chinese NSCLC patients with EGFR exon 20 insertion and post-Osimertinib EGFR-mutant patients, similar to the results of clinical trials conducted in western countries. Amivantamab was well tolerated and emphases should be put on adverse events such as rash, paronychia, and infusion-related reactions.【中文题目:Amivantamab治疗EGFR/MET基因异常 非小细胞肺癌的单中心经验】 【中文摘要:背景与目的 表皮生长因子受体(epidermal growth factor receptor, EGFR)和细胞间质上皮转换因子(cellular-mesenchymal to epithelial transition factor, c-Met)是非小细胞肺癌(non-small cell lung cancer, NSCLC)中常见的变异基因,都是受体酪氨酸激酶,在下游信号转导方面具有协同作用。针对EGFR和c-Met通路的靶向药物联合应用后,能够阻断PI3K/AKT/mTOR途径和Ras/Raf/Mek途径,限制补偿通路激活,发挥抗肿瘤作用。以Amivantamab为代表的EGFR和c-Met双特异性抗体新型药物能同时阻断两条信号通路,在肺癌临床研究中展现出良好前景。然而目前国内应用较少,相关经验缺乏。本研究将介绍我中心Amivantamab疗效数据和不良反应处理经验,探讨此类药物对我国EGFR/MET基因异常NSCLC的应用价值。方法 收集2020年8月-2021年12月于我院接受Amivantamab治疗的晚期NSCLC病例的临床数据,分析其治疗反应率、生存和不良反应。结果 本研究共纳入15例患者,其中Amivantamab单药治疗6例,Amivantamab联合Lazertinib治疗9例。治疗后7例(46.7%)达部分缓解(partial response, PR),7例(46.7%)达疾病稳定(stable disease, SD),1例(6.7%)达疾病进展(progressive disease, PD),总体客观缓解率(objective response rate, ORR)为46.7%,总体疾病控制率(disease control rate, DCR)为93.3%。7例EGFR外显子20插入突变患者中,2例(28.6%)达PR,5例(71.4%)达SD,DCR为100.0%,中位缓解持续时间(duration of response, DOR)未成熟,2例PR者仍持续缓解。5例奥希替尼耐药的患者中,2例(40.0%)达PR,3例(60.0%)达SD,DCR为100.0%,中位DOR未成熟,1例PR者仍持续缓解。中位随访时间为8.7个月(0.9个月-18.6个月),截至最后一次随访,共有6例患者发生疾病进展,3例患者死亡,中位无进展生存期和中位总生存期未成熟。常见的不良事件为皮疹(86.7%),甲沟炎(80.0%)和输液反应(60.0%),多为1级-2级。3级及以上不良反应包括皮疹(33.3%),转氨酶升高(13.3%)、水肿(6.7%)、血栓栓塞(6.7%)、间质性肺炎(6.7%)和血小板减低(6.7%)。结论 Amivantamab对EGFR外显子20插入突变和奥希替尼耐药的中国晚期NSCLC治疗有效,与国外疗效数据相仿。整体安全性可耐受,需重点关注皮疹、甲沟炎、输液反应等不良反应。 】 【中文关键词:肺肿瘤;EGFR;MET;靶向治疗;Amivantamab】.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
CodeCraft应助大橙子采纳,获得10
2秒前
量子星尘发布了新的文献求助10
3秒前
jeeya完成签到,获得积分10
4秒前
6秒前
科目三应助科研通管家采纳,获得10
6秒前
科目三应助科研通管家采纳,获得10
6秒前
伦语发布了新的文献求助10
6秒前
顾矜应助科研通管家采纳,获得10
6秒前
xuzj应助科研通管家采纳,获得10
6秒前
xuzj应助科研通管家采纳,获得10
6秒前
6秒前
NexusExplorer应助科研通管家采纳,获得10
6秒前
6秒前
6秒前
丘比特应助科研通管家采纳,获得10
7秒前
yull完成签到,获得积分10
7秒前
小巧书雪完成签到,获得积分10
10秒前
大大怪将军完成签到,获得积分10
11秒前
哈哈哈完成签到 ,获得积分0
11秒前
小怪完成签到,获得积分10
12秒前
爱吃泡芙完成签到,获得积分10
13秒前
白桃战士完成签到,获得积分10
14秒前
16秒前
qingchenwuhou完成签到 ,获得积分10
16秒前
XXX完成签到,获得积分10
17秒前
锡嘻完成签到 ,获得积分10
17秒前
18秒前
彗星入梦完成签到 ,获得积分10
18秒前
恋恋青葡萄完成签到,获得积分10
18秒前
隐形万言完成签到,获得积分10
20秒前
Time完成签到,获得积分10
20秒前
土木研学僧完成签到,获得积分10
21秒前
yjy完成签到 ,获得积分10
21秒前
A溶大美噶完成签到,获得积分10
21秒前
yar应助萨尔莫斯采纳,获得10
22秒前
Will发布了新的文献求助10
22秒前
美好的鹏笑完成签到,获得积分10
24秒前
啦啦啦啦啦完成签到,获得积分10
24秒前
LYegoist完成签到,获得积分10
26秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022